Xie Y, Hou W, Song X, Yu Y, Huang J, Sun X, Kang R, Tang D
Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Cell Death Differ. 2016 Mar;23(3):369-79. doi: 10.1038/cdd.2015.158. Epub 2016 Jan 22.
Ferroptosis is a recently recognized form of regulated cell death. It is characterized morphologically by the presence of smaller than normal mitochondria with condensed mitochondrial membrane densities, reduction or vanishing of mitochondria crista, and outer mitochondrial membrane rupture. It can be induced by experimental compounds (e.g., erastin, Ras-selective lethal small molecule 3, and buthionine sulfoximine) or clinical drugs (e.g., sulfasalazine, sorafenib, and artesunate) in cancer cells and certain normal cells (e.g., kidney tubule cells, neurons, fibroblasts, and T cells). Activation of mitochondrial voltage-dependent anion channels and mitogen-activated protein kinases, upregulation of endoplasmic reticulum stress, and inhibition of cystine/glutamate antiporter is involved in the induction of ferroptosis. This process is characterized by the accumulation of lipid peroxidation products and lethal reactive oxygen species (ROS) derived from iron metabolism and can be pharmacologically inhibited by iron chelators (e.g., deferoxamine and desferrioxamine mesylate) and lipid peroxidation inhibitors (e.g., ferrostatin, liproxstatin, and zileuton). Glutathione peroxidase 4, heat shock protein beta-1, and nuclear factor erythroid 2-related factor 2 function as negative regulators of ferroptosis by limiting ROS production and reducing cellular iron uptake, respectively. In contrast, NADPH oxidase and p53 (especially acetylation-defective mutant p53) act as positive regulators of ferroptosis by promotion of ROS production and inhibition of expression of SLC7A11 (a specific light-chain subunit of the cystine/glutamate antiporter), respectively. Misregulated ferroptosis has been implicated in multiple physiological and pathological processes, including cancer cell death, neurotoxicity, neurodegenerative diseases, acute renal failure, drug-induced hepatotoxicity, hepatic and heart ischemia/reperfusion injury, and T-cell immunity. In this review, we summarize the regulation mechanisms and signaling pathways of ferroptosis and discuss the role of ferroptosis in disease.
铁死亡是一种最近才被认识到的程序性细胞死亡形式。其形态学特征为线粒体比正常的小,线粒体膜密度浓缩,线粒体嵴减少或消失,以及线粒体外膜破裂。它可由实验性化合物(如艾拉司群、Ras选择性致死小分子3和丁硫氨酸亚砜胺)或临床药物(如柳氮磺吡啶、索拉非尼和青蒿琥酯)在癌细胞和某些正常细胞(如肾小管细胞、神经元、成纤维细胞和T细胞)中诱导产生。线粒体电压依赖性阴离子通道和丝裂原活化蛋白激酶的激活、内质网应激的上调以及胱氨酸/谷氨酸反向转运体的抑制都参与了铁死亡的诱导。这个过程的特征是脂质过氧化产物和源自铁代谢的致命活性氧(ROS)的积累,并且可以被铁螯合剂(如去铁胺和甲磺酸去铁胺)和脂质过氧化抑制剂(如铁抑素、脂氧素和齐留通)药理学抑制。谷胱甘肽过氧化物酶4、热休克蛋白β-1和核因子红细胞2相关因子2分别通过限制ROS产生和减少细胞铁摄取,作为铁死亡的负调节因子发挥作用。相反,NADPH氧化酶和p53(特别是乙酰化缺陷型突变体p53)分别通过促进ROS产生和抑制SLC7A11(胱氨酸/谷氨酸反向转运体的一种特异性轻链亚基)的表达,作为铁死亡的正调节因子发挥作用。铁死亡调节异常与多种生理和病理过程有关,包括癌细胞死亡、神经毒性、神经退行性疾病、急性肾衰竭、药物性肝毒性、肝脏和心脏缺血/再灌注损伤以及T细胞免疫。在这篇综述中,我们总结了铁死亡的调节机制和信号通路,并讨论了铁死亡在疾病中的作用。